What are the maximum recommended daily doses for all psychiatric medications?

Maximum Recommended Daily Doses for Psychiatric Medications

The evidence provided focuses primarily on specific clinical contexts (Alzheimer's disease, neuropathic pain, early psychosis, delirium) rather than comprehensive maximum dosing across all psychiatric medications. However, I can extract the following maximum doses from the available guidelines:

Antipsychotic Medications

Atypical (Second-Generation) Antipsychotics

For behavioral symptoms in Alzheimer's disease 1:

• Risperidone: 2-3 mg/day (divided doses; extrapyramidal symptoms may occur at 2 mg/day)
• Olanzapine: 10 mg/day (divided doses; generally well tolerated)
• Quetiapine: 400 mg/day (200 mg twice daily; more sedating with orthostatic hypotension risk)

For delirium in cancer patients 2:

• Olanzapine: dose not specified as maximum (start 2.5-5 mg)
• Quetiapine: dose not specified as maximum (start 25 mg)
• Risperidone: 6 mg/24h (increased extrapyramidal side effect risk above this dose)
• Aripiprazole: dose not specified as maximum (start 5 mg daily)

For early psychosis 3:

• Risperidone: 2 mg/day (initial target dose for most first-episode patients)
• Olanzapine: 7.5-10 mg/day (initial target dose; maximum 20 mg/day mentioned elsewhere)

For schizophrenia (INTEGRATE guidelines) 4:

• Clozapine: titrate to plasma level 350-550 ng/mL (doses above 550 ng/mL have diminishing returns with number needed to treat of 17; seizure risk increases)

Typical (First-Generation) Antipsychotics

For behavioral symptoms in Alzheimer's disease 1:

• Haloperidol: 4-6 mg maximum in first-episode psychosis 3 (or equivalent)
• Specific maximum doses for fluphenazine, thiothixene, trifluoperazine, molindone, perphenazine, and loxapine vary by agent but are not specified in provided evidence

Antidepressant Medications

Tricyclic Antidepressants (TCAs)

For neuropathic pain 5:

• Nortriptyline or Desipramine: 150 mg/day (can continue cautiously if blood concentration <100 ng/mL)

For depression in Alzheimer's disease 1:

• Desipramine: 150 mg/day (morning dosing)
• Nortriptyline: 40 mg/day (divided doses)

General cardiac safety recommendation 5: Limit TCA doses to <100 mg/day when possible in patients with cardiac risk factors

For therapeutic drug monitoring 6:

• Amitriptyline plus nortriptyline: 80-200 ng/mL (therapeutic range, not maximum dose)
• Nortriptyline: 70-170 ng/mL (therapeutic window)
• Imipramine plus desipramine: 175-300 ng/mL (therapeutic range)
• Clomipramine plus norclomipramine: 175-450 ng/mL (therapeutic range)

Selective Serotonin Reuptake Inhibitors (SSRIs)

For adolescent depression 7:

• Citalopram: 60 mg/day
• Fluoxetine: 60 mg/day (FDA-approved for pediatric depression)
• Fluvoxamine: 300 mg/day
• Paroxetine: 60 mg/day (not recommended to start in primary care)
• Sertraline: 200 mg/day
• Escitalopram: 20 mg/day (FDA-approved for adolescents ≥12 years)

Important caveat 8: FDA and EMA have limited maximum doses of citalopram and escitalopram due to QT prolongation risk, with further reductions for patients >60 years, though specific reduced doses are not provided in the evidence.

For depression in Alzheimer's disease 1:

• Fluoxetine: 20 mg/day (morning dosing)
• Paroxetine: 40 mg/day
• Sertraline: 200 mg/day
• Citalopram: 40 mg/day
• Fluvoxamine: 300 mg/day (150 mg twice daily)

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

For neuropathic pain 5:

• Duloxetine: 120 mg/day (60 mg twice daily)
• Venlafaxine: 225 mg/day (efficacious range 150-225 mg/day)

Other Antidepressants

For depression in Alzheimer's disease 1:

• Nefazodone: 300-600 mg/day (150-300 mg twice daily)
• Bupropion: 300 mg/day (150 mg twice daily)
• Mirtazapine: 30 mg/day (bedtime dosing)

For therapeutic drug monitoring 6:

• Trazodone: 650-1500 ng/mL (therapeutic range)

Mood Stabilizers/Anticonvulsants

For behavioral symptoms in Alzheimer's disease 1:

• Trazodone: 200-400 mg/day (divided doses)
• Carbamazepine: titrate to therapeutic blood level 4-8 mcg/mL (starting 100 mg twice daily)
• Divalproex sodium: titrate to therapeutic blood level 40-90 mcg/mL (starting 125 mg twice daily)

For neuropathic pain 5:

• Gabapentin: 3600 mg/day (in 3 divided doses; requires renal adjustment)
• Pregabalin: 600 mg/day (200 mg three times daily or 300 mg twice daily; requires renal adjustment)

For mood stabilization 1:

• Lithium: target blood level 0.2-0.6 mEq/L (typically achieved with 150-300 mg/day in elderly; higher in younger adults)

Benzodiazepines

For delirium management 2:

• Midazolam: 5 mg maximum per dose (2.5 mg subcutaneous/IV every 1 hour as needed; lower in elderly/frail)
• Lorazepam: 2 mg maximum per dose (1 mg subcutaneous/IV stat; lower in elderly/frail)

Critical Caveats and Clinical Considerations

Population-Specific Adjustments

Elderly patients require substantially lower doses across all medication classes 1, 5, 1, 8. The evidence consistently shows:

• TCAs should be limited to <100 mg/day when possible in patients >40 years with cardiac risk
• Citalopram and escitalopram have further reduced maximums for patients >60 years
• Antipsychotics in elderly dementia patients require doses far below standard adult maximums

Cardiac Safety Monitoring

QT prolongation risk 8:

• TCAs, citalopram, escitalopram, and typical antipsychotics all prolong QT interval
• Baseline ECG recommended for patients >40 years starting TCAs
• Methadone causes pronounced QT prolongation; ECG monitoring recommended when dose exceeds 120 mg/day

Renal Function

Dose reduction required 5:

• Gabapentin and pregabalin require adjustment based on creatinine clearance
• Metformin (used adjunctively with antipsychotics) contraindicated in renal failure

First-Episode Psychosis

Lower doses are appropriate 3: Maximum 4-6 mg haloperidol equivalent in first-episode psychosis, with target doses of risperidone 2 mg/day or olanzapine 7.5-10 mg/day to minimize extrapyramidal symptoms and encourage adherence.

Therapeutic Drug Monitoring

Blood level monitoring is strongly recommended for several medications 6:

• Nortriptyline has a therapeutic "window" of 50-150 ng/mL
• Lithium requires regular monitoring (target 0.2-0.6 mEq/L in elderly)
• Clozapine should target plasma levels of 350-550 ng/mL 4

Important Limitation

The provided evidence does not comprehensively cover maximum doses for all psychiatric medications. Notably absent are specific maximum doses for many commonly used medications in general adult psychiatric practice, mood stabilizers like lamotrigine, and newer antipsychotics. The doses provided are context-specific (elderly, first-episode, specific conditions) and may not represent absolute maximums for all clinical situations. Consult current prescribing information and specialized references for medications not covered here.